^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    camonsertib (RP-3500)

    i
    Other names: RP-3500, RG6526, RG 6526, RG-6526, RP 3500, RP3500
    Associations

    News

    Trials
    Company:
    Repare Therap
    Drug class:
    ATR inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=84 --> 49
    Enrollment closed • Enrollment change
    |
    ATM (ATM serine/threonine kinase)
    |
    ATM mutation
    |
    camonsertib (RP-3500)
    4d
    Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=39, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date • Tumor mutational burden
    |
    camonsertib (RP-3500)
    7d
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    1m
    A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1/2, N=84, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    ATM (ATM serine/threonine kinase)
    |
    ATM mutation
    |
    camonsertib (RP-3500)
    2ms
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Nov 2026 --> Nov 2025
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    2ms
    ATTACC: Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=156, Terminated, Repare Therapeutics | Trial completion date: Dec 2025 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Nov 2024; Sponsor decided to terminate study early therefore, the Phase 2 portion was not conducted
    Trial completion date • Trial termination • Trial primary completion date
    |
    Lynparza (olaparib) • Zejula (niraparib) • camonsertib (RP-3500)
    3ms
    TRESR: Study of RP-3500, Camonsertib, in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=276, Completed, Repare Therapeutics | Trial completion date: Dec 2025 --> Jun 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    gemcitabine • Talzenna (talazoparib) • camonsertib (RP-3500)
    5ms
    RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Canadian Cancer Trials Group | Recruiting --> Active, not recruiting | N=78 --> 28
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CCNE1 (Cyclin E1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation
    |
    Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (RP-6306) • camonsertib (RP-3500)
    7ms
    The cold immunological landscape of ATM-deficient cancers. (PubMed, J Immunother Cancer)
    ATM deficiency, while compromising DNA repair and enhancing sensitivity to radiation and ATR inhibition, does not increase tumor antigenicity or immunogenicity. Altogether, our results have important implications for the design of novel combination therapies for ATM null tumors and highlight the importance of antigenicity in the immunological consequences of defective DNA repair.
    Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    ATM (ATM serine/threonine kinase)
    |
    Lynparza (olaparib) • etoposide IV • camonsertib (RP-3500)
    9ms
    Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. (PubMed, Nat Commun)
    Mechanistically, low doses of RP-6306 with RP-3500 increase CDK1 activation more so than monotherapy, triggering rapid and robust induction of premature mitosis, DNA damage, and apoptosis in a CCNE1-dependent manner. These findings suggest that targeting CDK1 activity by combining RP-6306 with RP-3500 is an effective therapeutic approach to treat CCNE1-amplifed OVCAs and EMCAs.
    Journal
    |
    CCNE1 (Cyclin E1) • CDK1 (Cyclin-dependent kinase 1) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1)
    |
    lunresertib (RP-6306) • camonsertib (RP-3500)
    11ms
    TRESR: Study of RP-3500, Camonsertib, in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=285, Active, not recruiting, Repare Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • Talzenna (talazoparib) • camonsertib (RP-3500)
    12ms
    RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=78, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CCNE1 (Cyclin E1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1
    |
    Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (RP-6306) • camonsertib (RP-3500)